NCT01922661View on ClinicalTrials.gov

Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Allergy
Interventions
DRUG

REGN1908-1909

OTHER

placebo

Trial Locations (2)

Unknown

Overland Park

Baltimore

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT01922661 - Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects | Biotech Hunter | Biotech Hunter